

Contents

Advisory Board Members *xi*

Preface *xiii*

Part I General Aspects *1*

1	Drug Discovery in Academia	3
	<i>Oliver Plettenburg</i>	
1.1	Introduction	3
1.2	Repurposing Drugs	5
1.2.1	Thalidomide Derivatives	5
1.2.2	Chemotherapy: Nitrogen Mustards	6
1.3	Pregabalin	8
1.4	Natural Product-Derived Drug Discovery	10
1.4.1	Antibiotics	11
1.4.2	Anticancer Drugs	12
1.4.2.1	Camptothecin	12
1.4.2.2	Taxol	14
1.4.2.3	Epothilones	17
1.4.2.4	Eribulin	18
1.4.3	Artemisinin and Artemether	20
1.4.4	Carfilzomib	21
1.5	Biologic Drugs	23
1.5.1	Insulin	23
1.5.2	Rituximab	25
1.5.3	Alglucerase	26
1.6	Conceptually New Small Molecule Drugs	27
1.6.1	Histone Deacetylase Inhibitors	27
1.6.2	Acyclic Nucleoside Phosphonates	29
1.6.3	Darunavir	31
1.6.4	Sunitinib	32
1.7	Sweet Spot for Academic Drug Discovery	34
	List of Abbreviations	36

References 37

Biography 46

2 From Degraders to Molecular Glues: New Ways of Breaking Down Disease-Associated Proteins 47

Yvonne A. Nagel, Adrian Britschgi and Antonio Ricci

- 2.1 Introduction 47
- 2.2 Definition and Historical Development of Degraders 47
- 2.3 The Ubiquitin–Proteasome System and Considerations of E3 Ligases 53
- 2.4 General Design Aspects 55
- 2.5 Differentiation of the Degradation Technology to Traditional Approaches 58
 - 2.5.1 The Ability to Expand the Druggable Proteome 58
 - 2.5.2 Overcoming the Accumulation of Target Protein 59
 - 2.5.3 Abrogating Scaffolding Functions 59
 - 2.5.4 Creating Target Specificity 60
 - 2.5.5 Catalytic Mode of Action 60
 - 2.5.6 Event-Driven Pharmacology and Prolonged PD Effect 61
- 2.6 Potential Disadvantages and Limitations of Degraders 62
- 2.7 Molecular Glue-like Degraders and Monovalent Degraders 64
 - 2.7.1 Definitions and Historical Perspective 64
 - 2.7.2 State of the Art 67
- 2.8 Future Directions (Status Q3 2020) 70
- 2.9 Summary and Conclusions 71
 - Acknowledgments 71
 - List of Abbreviations 72
 - References 73
 - Biographies 84

Part II Drug Class Studies 87

3 GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity 89

Lars Linderoth, Jacob Kofoed, János T. Kodra, Steffen Reedtz-Runge and Thomas Kruse

- 3.1 Introduction 89
- 3.2 GLP-1 Biology 90
 - 3.2.1 GLP-1 Receptor Binding and Activation 91
 - 3.2.2 GLP-1 Pharmaceutical Developments 92
- 3.3 Ex4-Based Analogues 92
 - 3.3.1 Exenatide 92
 - 3.3.2 Exenatide LAR 94
 - 3.3.3 Lixisenatide 94
 - 3.3.4 Efglenatide 94

3.3.5	Pegylated Loxenatide	95
3.4	GLP-1 Based Analogues	95
3.4.1	Liraglutide	95
3.4.2	Semaglutide	96
3.4.3	Taspoglutide	97
3.4.4	Albiglutide and Albenatide	98
3.4.5	Dulaglutide	98
3.5	Co-agonists	99
3.5.1	GLP-1/GIP Co-agonists	100
3.5.2	GLP-1/Glucagon Co-agonists	100
3.5.2.1	Other GLP-1R Agonists	100
3.6	Summary	102
	List of Abbreviations	103
	References	104
	Biographies	108
4	Recent Advances on SGLT2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events	111
	<i>Ana M. de Matos, Patrícia Calado, William Washburn and Amélia P. Rauter</i>	
4.1	Introduction	111
4.2	The Mechanism of Action of SGLT2 Inhibitors	112
4.3	Synthetic Approaches to Gliflozins	113
4.3.1	Dapagliflozin	114
4.3.2	Sotagliflozin	119
4.3.3	Empagliflozin	119
4.3.4	Bexagliflozin	122
4.3.5	Luseogliflozin	123
4.3.6	Tofogliflozin	125
4.3.7	Ertugliflozin	128
4.3.8	Ipragliflozin	129
4.3.9	Canagliflozin	130
4.3.10	Remogliflozin	133
4.4	Clinical Benefits of SGLT2 Inhibitors	134
4.4.1	Reduction in HbA _{1c} Levels	134
4.4.2	Protection Against Cardiovascular Events in Diabetic Patients	137
4.4.3	Renoprotection in Patients with T2D	139
4.4.4	Bodyweight Reduction	140
4.5	Safety Profile and Particularly Relevant Adverse Events Associated with SGLT2 Inhibitors	141
4.6	Application of SGLT2 Inhibitors in Type 1 Diabetes	143
4.7	Conclusions	145
	Acknowledgments	146
	List of Abbreviations	146
	References	148
	Biographies	155

5	CAR T Cells: A Novel Biological Drug Class	159
	<i>Whitney Gladney, Julie Jadowsky, Megan M. Davis and Andrew Fesnak</i>	
5.1	Introduction	159
5.2	A Brief History of Cell-Based Therapies	159
5.3	Genetically Engineered T Cell Therapy Products	162
5.3.1	T Cell Receptor-Engineered T Cells	162
5.3.1.1	Intro to TCRs	162
5.3.1.2	Challenges with TCR-Engineered T Cells	165
5.3.2	CAR T Cells	165
5.3.2.1	What Is a CAR?	165
5.3.2.2	Why Do You Put a CAR into a T Cell (as Opposed to Another Cell)?	167
5.4	CAR T Cells: The Living Drug	169
5.4.1	Early Signals of CAR T Cell Efficacy	169
5.4.2	CART19 Pharmacokinetics	170
5.4.2.1	Expansion	170
5.4.2.2	Persistence	171
5.4.2.3	Trafficking	172
5.4.3	Biomarkers of CAR T Cell Quality	172
5.4.4	Side Effects of CAR T Cell Therapy	173
5.4.4.1	Cytokine Release Syndrome	173
5.4.4.2	CAR T Cell Associated Neurotoxicity	174
5.4.4.3	On-Target, Off-Tumor Toxicities	175
5.4.5	Challenges Encountered with Therapeutic Application of CAR T Cells	176
5.4.5.1	Production Issues	176
5.4.5.2	Therapeutic Resistance	179
5.5	Translation from Laboratory Innovation to Approved Therapy	183
5.6	Future Directions and CAR T Programs to Consider	186
5.6.1	Approved Therapies	186
5.6.2	Pre-registration Therapies	187
5.7	Additional Resources for Supplementary Information on Cellular Therapies, Including Regulations, Notifications, and Guidelines	188
	List of Abbreviations	190
	References	192
	Biographies	197
6	CGRP Inhibitors for the Treatment of Migraine	199
	<i>Sarah Walter and Marcelo E. Bigal</i>	
6.1	Introduction	199
6.2	The Overall Physiological Role of CGRP	200
6.3	The Role of CGRP in the Gut	203
6.4	What Is the Role of CGRP in Migraine?	203
6.4.1	Small-Molecule Antagonists	204
6.4.2	Large-Molecule Antagonists	208
6.5	Role of CGRP Antagonists in Other Indications	211
6.6	Conclusions	212

List of Abbreviations	212
References	213
Biographies	219

Part III Case Studies 221

7	Discovery and Development of Emicizumab (HEMLIBRA®): A Humanized Bispecific Antibody to Coagulation Factors IXa and X with a Factor VIII Cofactor Activity	223
	<i>Takehisa Kitazawa, Koichiro Yoneyama and Tomoyuki Igawa</i>	
7.1	Introduction	223
7.2	Preclinical Experience with Emicizumab	225
7.2.1	Brief History on Discovery of Emicizumab	225
7.2.1.1	Idea Inspiration of an Asymmetric Bispecific IgG Antibody to FIXa and FX with FVIII-Cofactor Function	225
7.2.1.2	From the First Immunization to the Identification of the Clinical Candidate (ACE910 = Emicizumab)	226
7.2.2	Mechanism of Action and Nonclinical Characteristics of Emicizumab	229
7.2.2.1	Mechanism of Action and <i>In Vitro</i> Characteristics of Emicizumab	229
7.2.2.2	<i>In Vivo</i> Characteristics of Emicizumab	230
7.2.3	Molecular Engineering Technologies Incorporated in Emicizumab for Industrial Manufacturing	231
7.2.3.1	Obtaining a Common Light Chain	232
7.2.3.2	Separation and Purification from By-products	232
7.2.3.3	Minimizing the Amount of Homodimeric By-products	233
7.2.3.4	Application of Technology	233
7.2.4	Conclusions from Preclinical Studies	233
7.3	Clinical Experience with Emicizumab	234
7.3.1	Early-Phase Clinical Development	235
7.3.1.1	Phase I and I/II Studies	235
7.3.1.2	Clinical Pharmacology Investigations	237
7.3.2	Late-Phase Clinical Development	239
7.3.2.1	Non-interventional Study	239
7.3.2.2	Phase III Studies with Once-Weekly Dosing in Patients with FVIII Inhibitors	239
7.3.2.3	Phase III Studies with Once-Weekly, Every-2-Week, or Every-4-Week Dosing in Patients with or without FVIII Inhibitors	240
7.4	Conclusions	242
	Acknowledgments	242
	Conflict of Interests	242
	List of Abbreviations	243
	References	243
	Biographies	247

8	Discovery and Development of Ivosidenib (AG-120: TIBSOVO®)	249
	<i>Zenon D. Konteatis and Zhihua Sui</i>	
8.1	Introduction	249
8.2	Crystal Structure of IDH1	250
8.3	Search for mIDH1 Inhibitors	250
8.4	Hit to Lead Exploration	252
8.5	Lead Optimization: Discovery of AG-120	257
8.6	Synthesis of AG-120	260
8.7	Preclinical Characterization of AG-120	261
8.8	Ivosidenib Clinical Studies	262
8.9	Conclusions	267
	List of Abbreviations	268
	References	268
	Biographies	270
9	The Discovery of Kisqali® (Ribociclib): A CDK4/6 Inhibitor for the Treatment of HR+/HER2– Advanced Breast Cancer	273
	<i>Christopher T. Brain, Rajiv Chopra, Sunkyu Kim, Steven Howard and Moo Je Sung</i>	
9.1	Disease Background	273
9.2	Target Background and Validation: The Cell Cycle	274
9.3	Commencement of Drug Discovery Efforts	276
9.4	Fragment-based Approach	276
9.5	Cross-Screening of Existing Kinase Assets Leading to Ribociclib	277
9.6	Combination Treatments with Ribociclib	282
9.7	Early-Phase Clinical Studies	283
9.8	Phase 3 Clinical Studies	284
9.9	Conclusions	285
	Acknowledgments	285
	List of Abbreviations	285
	References	286
	Biographies	288
	Index	291